Cargando…

Pulmonary vasodilator therapy in sarcoidosis‐associated pulmonary hypertension may decrease lung function decline and mortality

The efficacy of treating sarcoidosis‐associated pulmonary hypertension (SAPH) with pulmonary vasodilator therapy is unclear. The INCREASE trial showed improvement in 6‐minute walk distance (6MWD) and in decline in functional vital capacity (FVC) in patients with interstitial lung disease and pulmona...

Descripción completa

Detalles Bibliográficos
Autores principales: Gayen, Shameek, Ansari, Sohaib, Lashari, Bilal H., Zhao, Huaqing, Criner, Gerard J., Gupta, Rohit, James Mamary, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241350/
https://www.ncbi.nlm.nih.gov/pubmed/37284520
http://dx.doi.org/10.1002/pul2.12245